NCT06284798View on ClinicalTrials.gov

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

PHASE1CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions

Healthy Participants

Interventions

DRUG

NNC0650-0013 A

NNC0650-0013 will be administered subcutaneously or intravenously.

DRUG

Placebo

Subcutaneous administration.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY